RULE NO: RULE TITLE
64B16-28.605: Class II Institutional Pharmacies – Automated Distribution and Packaging
The change is in response to written comments submitted by the staff of the Joint Administrative Procedures Committee. The changes are as follows:
(1) Subsection (1)(f) shall now read as follows:
(f) “Override medication” means a single dose of medication that may be removed from a decentralized automated medication system prior to pharmacist review because a practitioner licensed pursuant to Chapter 458, Chapter 459, or Chapter 466, Florida Statutes, has determined that the clinical status of the patient would be significantly compromised by delay.
(2) Subsection (1)(g) shall now read as follows:
(g) “Low risk override medication” is a medication determined by a practitioner licensed pursuant to Chapter 458, Chapter 459, or Chapter 466, Florida Statutes, to have a low risk of drug allergy, drug interaction, dosing error, or adverse patient outcome, and may be removed from a decentralized automated medication system independent of a pharmacist’s review of the medication order or clinical status of the patient.
(3) Subsection (2)(a)3.a. shall now read as follows:
a. Operation of the automated medication system;
(4) Subsection (3)(b)4. shall now read as follows:
4. Have its decisions reviewed and approved by the consultant pharmacist of record.
(5) Subsection (9) shall now read as follows:
(9) Security. A decentralized automated medication system that contains controlled substances shall prohibit simultaneous access to multiple drug entities, drug strengths, or dosage forms of controlled substances, unless otherwise contained in labeled patient-specific form.
(6) Section 465.0235, F.S. will be added to the Law Implemented.